ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Pharmaceuticals

Daiichi Sankyo and Nichi-Iko to develop COVID-19 inhalation drug

Japanese companies see the method as a more effective coronavirus treatment

Japanese pharmaceutical companies Daiichi Sankyo and Nichi-Iko are launching a project to develop a potential inhalation treatment for the coronavirus.

TOKYO -- Japanese pharmaceutical companies Daiichi Sankyo and Nichi-Iko, in cooperation with the University of Tokyo, will work to develop a potential inhalation treatment for the coronavirus, the parties announced Monday.

The project will focus on turning Nichi-Iko's protease inhibitor Futhan, a candidate treatment for COVID-19, into an inhalation preparation to make it more effective.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more